The Centers for Medicare and Medicaid services proposed a new set of policies that appear to expand the use of a procedure that allows doctors to replace the aortic heart valve without performing open-heart surgery.

The procedure, called transcatheter aortic valve replacement (TAVR), was first introduced as an alternative to surgical aortic valve replacement (SAVR) for the sickest patients, but its use has gradually expanded to more and more patients as clinical trials showed that the catheter-based approach was as good or, in some ways, better. The two leading makers of TAVR are Edwards Lifesciences, the market leader, and Medtronic.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy